Key terms
About SGMO
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SGMO news
Mar 22
8:10am ET
Sangamo to sell 24.761M shares at 84c
Mar 19
6:21am ET
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Intuitive Surgical (ISRG) and Sangamo Biosciences (SGMO)
Mar 19
6:07am ET
Sangamo price target raised to $5 from $3 at H.C. Wainwright
Mar 15
9:50pm ET
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Mar 14
9:55am ET
Sangamo Biosciences: A Buy Rating on Strong Gene Therapy and CNS Program Prospects
Mar 14
7:25am ET
Truist Financial Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)
Mar 14
6:28am ET
Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements
Mar 14
6:17am ET
Sangamo Biosciences: Hold Rating Amid Financial Uncertainties and Promising Scientific Developments
Mar 14
5:00am ET
Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)
Mar 14
2:01am ET
Sangamo Biosciences on the Brink: Cash Crunch Could Lead to Bankruptcy by Q3 2024
Mar 13
12:35pm ET
Sangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy Rating
Mar 13
8:19am ET
Sangamo anounces data from neurotropic AAV capsid showing BBB penetration
Mar 13
8:08am ET
Sangamo reports Q4 EPS (34c), consensus (26c)
Mar 13
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 13, 2024
Mar 12
8:08am ET
Rigel Pharmaceuticals names Lisa Rojkjaer, M.D. as Chief Medical Officer
Mar 07
3:34pm ET
Sangamo options imply 14.1% move in share price post-earnings
Feb 29
8:45am ET
Largest borrow rate increases among liquid names
Feb 16
6:57am ET
Sangamo Biosciences: A Strong Buy on Gene Therapy Innovation and Strategic Partnership Potential
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Feb 13
5:50am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 13
5:38am ET
Sangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial Uncertainties
Feb 12
8:09am ET
Sangamo announces FDA alignment on ST-920 pathway, EMA prime eligibility
Feb 07
5:05am ET
Sangamo’s STAAR Study Shows Promise in Fabry Disease Treatment
Feb 06
8:46am ET
Buy Rating Affirmed for Sangamo Biosciences on Promising Gene Therapy for Fabry Disease and Solid Management Strategy
Feb 05
6:06pm ET
Sangamo announces updated Phase 1/2 STAAR study data in fabry disease
Feb 05
2:32pm ET
Sangamo’s isaralgagene civaparvovec granted EMA PRIME designation
Jan 22
1:48pm ET
Buy Rating Affirmed for Sangamo Biosciences on Promising Neurology Pivot and Pipeline Potential
Jan 12
5:53am ET
Sangamo Biosciences: A Cautious Hold Amidst Strategic Partnerships and Financial Considerations
No recent press releases are available for SGMO
SGMO Financials
Key terms
Ad Feedback
SGMO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SGMO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
